HK1210230A1 - 用於提供前列腺癌的臨床評估的方法、試劑盒和組合物 - Google Patents

用於提供前列腺癌的臨床評估的方法、試劑盒和組合物

Info

Publication number
HK1210230A1
HK1210230A1 HK15110940.3A HK15110940A HK1210230A1 HK 1210230 A1 HK1210230 A1 HK 1210230A1 HK 15110940 A HK15110940 A HK 15110940A HK 1210230 A1 HK1210230 A1 HK 1210230A1
Authority
HK
Hong Kong
Prior art keywords
kits
compositions
methods
providing
prostate cancer
Prior art date
Application number
HK15110940.3A
Other languages
English (en)
Inventor
‧海伊斯
‧博德裡
‧弗雷德
‧帕克特
Original Assignee
Diagnocure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnocure Inc filed Critical Diagnocure Inc
Publication of HK1210230A1 publication Critical patent/HK1210230A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/24—Classification techniques
    • G06F18/241—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches
    • G06F18/2411—Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches based on the proximity to a decision surface, e.g. support vector machines
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/24—Classification techniques
    • G06F18/243—Classification techniques relating to the number of classes
    • G06F18/24323—Tree-organised classifiers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
HK15110940.3A 2012-07-20 2015-11-05 用於提供前列腺癌的臨床評估的方法、試劑盒和組合物 HK1210230A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261674079P 2012-07-20 2012-07-20
PCT/CA2013/050452 WO2014012176A1 (en) 2012-07-20 2013-06-14 Methods, kits and compositions for providing a clinical assessment of prostate cancer

Publications (1)

Publication Number Publication Date
HK1210230A1 true HK1210230A1 (zh) 2016-04-15

Family

ID=49948136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110940.3A HK1210230A1 (zh) 2012-07-20 2015-11-05 用於提供前列腺癌的臨床評估的方法、試劑盒和組合物

Country Status (6)

Country Link
US (1) US20150218646A1 (zh)
EP (1) EP2875157A4 (zh)
CN (1) CN104603292A (zh)
CA (1) CA2879557A1 (zh)
HK (1) HK1210230A1 (zh)
WO (1) WO2014012176A1 (zh)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105095921B (zh) * 2014-04-30 2019-04-30 西门子医疗保健诊断公司 用于处理尿液沉渣图像的待处理区块的方法和装置
CN105096294B (zh) * 2014-04-30 2019-01-18 西门子医疗保健诊断公司 用于对尿液沉渣图像的待处理区块进行区块检索的方法和装置
WO2016087430A1 (en) * 2014-12-01 2016-06-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel RNA-biomarker signature for diagnosis of prostate cancer
EP3037545A1 (en) * 2014-12-23 2016-06-29 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A DNA-methylation test for prostate cancer
WO2016193109A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
EP3304082B1 (en) * 2015-06-08 2020-05-13 Arquer Diagnostics Limited Methods for analysing a urine sample
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
US10585101B2 (en) * 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
CA3062573A1 (en) * 2017-05-12 2018-11-15 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene profiles and methods of using the same
CN109593835B (zh) * 2017-09-29 2023-12-12 深圳华大基因股份有限公司 用于微量ffpe rna样本评估的方法、试剂盒及应用
WO2019165021A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
US11530451B2 (en) 2018-03-02 2022-12-20 The Johns Hopkins University Methods for prostate cancer detection
SG11202009696WA (en) 2018-04-13 2020-10-29 Freenome Holdings Inc Machine learning implementation for multi-analyte assay of biological samples
CN108624691A (zh) * 2018-06-22 2018-10-09 杭州西合精准医疗科技有限公司 一种用于判断前列腺疾病的标志物及其应用
CN109086572A (zh) * 2018-07-24 2018-12-25 南方医科大学南方医院 一种用于评估胃癌术后预后和化疗反应性的试剂和方法
CN109628570A (zh) * 2018-12-07 2019-04-16 南方医科大学南方医院 一种检测TRIM29基因Tyr544Cys突变的试剂盒及其用途
CN109971850A (zh) * 2018-12-27 2019-07-05 李刚 一种辅助预测前列腺癌的液体活检方法及其应用
CN110760584B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌疾病进展生物标志物及其应用
CA3159461A1 (en) * 2019-11-25 2021-06-03 Iwao Ojima Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer
CN111312387A (zh) * 2020-01-16 2020-06-19 安徽医科大学第一附属医院 一种男性慢性前列腺炎/慢性盆腔痛综合征疼痛严重程度预测模型及其建立
CN117265123A (zh) * 2020-11-09 2023-12-22 廖红 前列腺癌症标志物基因组合及应用
US11636280B2 (en) * 2021-01-27 2023-04-25 International Business Machines Corporation Updating of statistical sets for decentralized distributed training of a machine learning model
CN113025721A (zh) * 2021-04-28 2021-06-25 苏州宏元生物科技有限公司 一种前列腺癌诊断和预后评估试剂盒
CN114774299A (zh) * 2022-05-16 2022-07-22 滨州医学院 代谢工程方法、产羊毛甾醇工程菌及其构建方法、应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5009787B2 (ja) * 2004-05-07 2012-08-22 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇ遺伝子を単独でまたは前立腺癌中で過剰発現もしくは過少発現される他の遺伝子と組み合わせて用いる、前立腺癌を診断または治療する方法
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
ES2611000T3 (es) * 2010-07-27 2017-05-04 Genomic Health, Inc. Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata

Also Published As

Publication number Publication date
CN104603292A (zh) 2015-05-06
US20150218646A1 (en) 2015-08-06
EP2875157A1 (en) 2015-05-27
CA2879557A1 (en) 2014-01-23
WO2014012176A1 (en) 2014-01-23
EP2875157A4 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
HK1210230A1 (zh) 用於提供前列腺癌的臨床評估的方法、試劑盒和組合物
IL257330B (en) Preparations, methods and kits for diagnosing lung cancer
EP2714081A4 (en) METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
HK1204302A1 (zh) 癌症免疫療法的組合物和方法
EP2904106A4 (en) COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER
IL304337A (en) Antiandrogens for the treatment of castration-resistant prostate cancer without metastases
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
HK1259001A1 (zh) 癌症的預後和診斷方法
EP2867376A4 (en) TARGETED METHODS KNOWN AS RNA-SEQ AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCER
GB201206209D0 (en) Marker gene based diagnosis, staging and prognosis of prostate caner
EP2707710A4 (en) DIAGNOSIS OF CANCER
EP2686447A4 (en) PROGNOSTIC MARKER SETS FOR PROSTATE CANCER
IL232466A (en) Preparations and Methods for Prostate Cancer Analysis
EP2836133A4 (en) ULTRASONIC PROBE / COHESIVE ROBOT FOR PROSTATE BIOPSY
IL238639A0 (en) Methods for using biomarkers to treat cancer by regulating bcl2 expression
EP2885429A4 (en) DIAGNOSTIC MARKERS FOR INDOLENT PROSTATE CANCER
HUE039389T2 (hu) Az anti-EMP2 terápia csökkenti a rák õssejteket
EP2699699A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2932273A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
EP2882869A4 (en) PROSTATE CANCER GENE EXPRESSION PROFILES
EP2812694A4 (en) TESTS AND METHODS FOR DIAGNOSING OVARIAN CANCER
EP2732287A4 (en) METHOD FOR THE DIAGNOSIS OF CANCER
EP2844347A4 (en) COMPOSITIONS AND METHODS FOR TREATING MALIGNANT B-LYMPHOID TUMORS
GB201222952D0 (en) Treatent of cancer
IL229109B (en) Cancer diagnosis